Tosoh Bioscience

Articles by Tosoh Bioscience

Traditionally, producing biotherapeutics such as monoclonal antibodies required a multi-step process to remove impurities, including host-cell proteins, DNA, adventitious viruses, and antibody aggregates. However, by converting the process from batch chromatography to multi-column chromatography (MCC), there is potential to reduce costs and shorten production times for the capture and purification of high-quality mAbs.

Intensified continuous chromatography, a type of Multi-Column Chromatography (MCC), has emerged as a valuable technique in downstream bioprocessing that enables increases in productivity. In this podcast, MCC Product Specialist, Jennifer Knister, will discuss how adopting MCC can reduce costs, decrease suite time, and lead to higher resin utilization, along with why these benefits are particularly worthwhile in multi-product facilities.

Intensified continuous chromatography, a type of Multi-Column Chromatography (MCC), has emerged as a valuable technique in downstream bioprocessing that enables increases in productivity. In this podcast, MCC Product Specialist, Jennifer Knister, will discuss how adopting MCC can reduce costs, decrease suite time, and lead to higher resin utilization, along with why these benefits are particularly worthwhile in multi-product facilities.

Using a pre-packed column platform enables seamless scale-up for downstream process purification. We demonstrate that neither the capacity of the packed resin nor the separation efficiency is affected when increasing the column volume.

i1-432401-1408662835736.jpg

A new, very high capacity cation exchange resin* for process scale applications was developed by the researchers at Tosoh Corporation. This resin, with dynamic binding capacities approaching 145 mg/mL for IgG molecules, is the newest member of the Toyopearl product line.